Ab&B Bio-Tech's (HKG:2627) new drug application for the quadrivalent subunit influenza vaccine for individuals aged six to 35 months was approved by China's National Medical Products Administration, a Wednesday Hong Kong bourse filing said.
Ab&B Bio-Tech's (HKG:2627) new drug application for the quadrivalent subunit influenza vaccine for individuals aged six to 35 months was approved by China's National Medical Products Administration, a Wednesday Hong Kong bourse filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.